Evidence map›Paper›PMID 42428079›Full record

ArticlemedRxiv : the preprint server for health sciences2026

Subtyping and staging of Alzheimer's disease from routine structural MRI with PHASE-AD.

Hannah Baumeister, Falk Lüsebrink, Luca Kleineidam, Niels Hansen, Matthias Schmid, Alexis Moscoso, Antoine Leuzy, Sophie E Mastenbroek, Colin Groot, Frederic Brosseron and 38 more

Abstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in medRxiv : the preprint server for health sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

48 authors.

Hannah BaumeisterGerman Center for Neurodegenerative Diseases (DZNE), Magdeburg, Germany.
Falk LüsebrinkGerman Center for Neurodegenerative Diseases (DZNE), Magdeburg, Germany.
Luca KleineidamGerman Center for Neurodegenerative Diseases (DZNE), Bonn, Germany.
Niels HansenDepartment of Psychiatry and Psychotherapy, University Medical Center Goettingen, University of Goettingen, Goettingen, Germany.
Matthias SchmidGerman Center for Neurodegenerative Diseases (DZNE), Bonn, Germany.
Alexis MoscosoZRO Imaging, Santiago de Compostela, Spain.
Antoine LeuzyZRO Imaging, Santiago de Compostela, Spain.
Sophie E MastenbroekClinical Memory Research Unit, Department of Clinical Sciences Malmö, Faculty of Medicine, Lund University, Lund, Sweden.
Colin GrootAlzheimer Center Amsterdam, Neurology, Vrije Universiteit Amsterdam, Amsterdam UMC, Amsterdam, Netherlands.
Frederic BrosseronGerman Center for Neurodegenerative Diseases (DZNE), Bonn, Germany.
Alfredo RamirezGerman Center for Neurodegenerative Diseases (DZNE), Bonn, Germany.
Lukas PreisDepartment of Psychiatry and Neurosciences, Charité - Universitätsmedizin Berlin, Berlin, Germany.
Daria GrefDepartment of Psychiatry and Neurosciences, Charité - Universitätsmedizin Berlin, Berlin, Germany.
Eike J SpruthGerman Center for Neurodegenerative Diseases (DZNE), Berlin, Germany.
Maria GemenetziGerman Center for Neurodegenerative Diseases (DZNE), Berlin, Germany.
Slawek AltensteinGerman Center for Neurodegenerative Diseases (DZNE), Berlin, Germany.
Klaus FliessbachGerman Center for Neurodegenerative Diseases (DZNE), Bonn, Germany.
Okka KimmichGerman Center for Neurodegenerative Diseases (DZNE), Bonn, Germany.
Björn H SchottDepartment of Psychiatry and Psychotherapy, University Medical Center Goettingen, University of Goettingen, Goettingen, Germany.
Ayda RostamzadehDepartment of Psychiatry, Medical Faculty, University of Cologne, Cologne, Germany.
Wenzel GlanzGerman Center for Neurodegenerative Diseases (DZNE), Magdeburg, Germany.
Enise I IncesoyGerman Center for Neurodegenerative Diseases (DZNE), Magdeburg, Germany.
Michaela ButrynGerman Center for Neurodegenerative Diseases (DZNE), Magdeburg, Germany.
Daniel JanowitzGerman Center for Neurodegenerative Diseases (DZNE), Munich, Germany.
Boris-Stephan RauchmannDepartment of Neuroradiology, University Hospital, LMU Munich, Munich, Germany.
Mihovil MladinovGerman Center for Neurodegenerative Diseases (DZNE), Rostock-Greifswald, Germany.
Alice GraziaDepartment of Psychosomatic Medicine and Psychotherapy, University of Rostock, Rostock, Germany.
Sebastian SodenkampGerman Center for Neurodegenerative Diseases (DZNE), Tübingen, Germany.
Tony StöckerGerman Center for Neurodegenerative Diseases (DZNE), Bonn, Germany.
Stefan HetzerBerlin Center for Advanced Neuroimaging, Charité - Universitätsmedizin Berlin, Berlin, Germany.
Peter DechentMR-Research in Neurosciences, Department of Cognitive Neurology, University Medical Center Goettingen, Goettingen, Germany.
Sophia StoeckleinGerman Center for Neurodegenerative Diseases (DZNE), Munich, Germany.
Alzheimer’s Disease Repository Without Borders Investigators
Alzheimer’s Disease Neuroimaging Initiative
DELCODE study group, Oliver Peters
Julian Hellmann-RegenDepartment of Psychiatry and Neurosciences, Charité - Universitätsmedizin Berlin, Berlin, Germany.
Josef PrillerGerman Center for Neurodegenerative Diseases (DZNE), Berlin, Germany.
Anja SchneiderGerman Center for Neurodegenerative Diseases (DZNE), Bonn, Germany.
Jens WiltfangDepartment of Psychiatry and Psychotherapy, University Medical Center Goettingen, University of Goettingen, Goettingen, Germany.
Katharina BuergerGerman Center for Neurodegenerative Diseases (DZNE), Munich, Germany.
Robert PerneczkyGerman Center for Neurodegenerative Diseases (DZNE), Munich, Germany.
Stefan TeipelGerman Center for Neurodegenerative Diseases (DZNE), Rostock, Germany.
Christoph LaskeGerman Center for Neurodegenerative Diseases (DZNE), Tübingen, Germany.
Annika SpottkeGerman Center for Neurodegenerative Diseases (DZNE), Bonn, Germany.
Michael WagnerGerman Center for Neurodegenerative Diseases (DZNE), Bonn, Germany.
Frank JessenGerman Center for Neurodegenerative Diseases (DZNE), Bonn, Germany.
Emrah DüzelGerman Center for Neurodegenerative Diseases (DZNE), Magdeburg, Germany.
David BerronGerman Center for Neurodegenerative Diseases (DZNE), Magdeburg, Germany.

Funding

Alzheimer's Disease Neuroimaging Initiative - SupplementU01AG024904 · NIA · NORTHERN CALIFORNIA INSTITUTE RES &EDUC · PI WEINER, MICHAEL W · 2004 to 2015
$121.0M
Technology and Remote Assessment CoreU19AG063911 · NIA · MAYO CLINIC ROCHESTER · PI ADAM L. BOXER · 2019 to 2026
$120.9M
Early Onset AD Consortium - the LEAD Study (LEADS)U01AG057195 · NIA · INDIANA UNIVERSITY INDIANAPOLIS · PI APOSTOLOVA, LIANA G, CARRILLO, MARIA C · 2018 to 2023
$70.3M
Smartphone-Based "Burst" Cognitive AssessmentsP01AG003991 · NIA · WASHINGTON UNIVERSITY · PI JOHN MORRIS · 1985 to 2026
$69.5M
The Clinical Significance of Incidental White Matter Lesions on MRI Amongst a Diverse Population with Cognitive Complaints (INDEED)U19NS120384 · NINDS · UNIVERSITY OF CALIFORNIA AT DAVIS · PI Kumar B. Rajan · 2020 to 2026
$61.9M
THERAPEUTIC EFFECTS OF INTRA-NASAL INSULIN DETEMIRP50AG005136 · NIA · UNIVERSITY OF WASHINGTON · PI GRABOWSKI, THOMAS J. · 1985 to 2019
$57.2M
The natural history of AB accumulation in preclinical ADP01AG026276 · NIA · WASHINGTON UNIVERSITY · PI MORRIS, JOHN · 2005 to 2025
$49.5M
SUPPLEMENT TO RUSH ALZHEIMERS DISEASE CENTER COREP30AG010161 · NIA · RUSH UNIVERSITY MEDICAL CENTER · PI BENNETT, DAVID ALAN · 1991 to 2020
$49.1M
Satellite Diagnostic and Treatment Clinic CoreP50AG008702 · NIA · COLUMBIA UNIV NEW YORK MORNINGSIDE · PI DE JAGER, PHILIP L · 1989 to 2019
$46.3M
National Alzheimer's Coordinating CenterU24AG072122 · NIA · UNIVERSITY OF WASHINGTON · PI STEPHENS, KARI A · 2021 to 2025
$45.8M
TREATMENT OF DEPRESSION IN ALZHEIMER'S DISEASEP50AG005133 · NIA · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI SWEET, ROBERT A · 1985 to 2019
$43.0M
Washington University Institute of Clinical and Translational SciencesUL1TR000448 · NCATS · WASHINGTON UNIVERSITY · PI EVANOFF, BRADLEY A · 2012 to 2016
$41.4M
NCATS NIH HHS UL1 TR000448NCRR NIH HHS U24 RR021382NIA NIH HHS P01 AG003991NIA NIH HHS P01 AG026276NIA NIH HHS P20 AG068053NIA NIH HHS P20 AG068077NIA NIH HHS P20 AG068082NIA NIH HHS P30 AG008017NIA NIH HHS P30 AG010129NIA NIH HHS P30 AG010133NIA NIH HHS P30 AG010161NIA NIH HHS P30 AG013846NIA NIH HHS P30 AG013854NIA NIH HHS P30 AG019610NIA NIH HHS P30 AG035982NIA NIH HHS P30 AG053760NIA NIH HHS P30 AG062421NIA NIH HHS P30 AG062422NIA NIH HHS P30 AG062428NIA NIH HHS P30 AG062429NIA NIH HHS P30 AG062677NIA NIH HHS P30 AG062715NIA NIH HHS P30 AG066444NIA NIH HHS P30 AG066462NIA NIH HHS P30 AG066468NIA NIH HHS P30 AG066506NIA NIH HHS P30 AG066507NIA NIH HHS P30 AG066508NIA NIH HHS P30 AG066509NIA NIH HHS P30 AG066511NIA NIH HHS P30 AG066512NIA NIH HHS P30 AG066514NIA NIH HHS P30 AG066515NIA NIH HHS P30 AG066518NIA NIH HHS P30 AG066519NIA NIH HHS P30 AG066530NIA NIH HHS P30 AG066546NIA NIH HHS P30 AG072931NIA NIH HHS P30 AG072946NIA NIH HHS P30 AG072947NIA NIH HHS P30 AG072958NIA NIH HHS P30 AG072959NIA NIH HHS P30 AG072972NIA NIH HHS P30 AG072973NIA NIH HHS P30 AG072975NIA NIH HHS P30 AG072976NIA NIH HHS P30 AG072977NIA NIH HHS P30 AG072978NIA NIH HHS P30 AG072979NIA NIH HHS P30 AG072980NIA NIH HHS P30 AG086401NIA NIH HHS P30 AG086403NIA NIH HHS P30 AG086404NIA NIH HHS P30 AG092752NIA NIH HHS P50 AG005133NIA NIH HHS P50 AG005136NIA NIH HHS P50 AG005142NIA NIH HHS P50 AG008702NIA NIH HHS P50 AG016573NIA NIH HHS P50 AG016574NIA NIH HHS P50 AG033514NIA NIH HHS P50 AG047266NIA NIH HHS P50 AG047270NIA NIH HHS P50 AG047366NIA NIH HHS R01 AG019771NIA NIH HHS R01 AG021910NIA NIH HHS R01 AG043434NIA NIH HHS R01 AG045571NIA NIH HHS R01 AG052560NIA NIH HHS R01 AG053509NIA NIH HHS R01 AG053993NIA NIH HHS R01 AG054110NIA NIH HHS R01 AG055005NIA NIH HHS R01 AG056031NIA NIH HHS R01 AG056258NIA NIH HHS R01 AG056531NIA NIH HHS R01 AG058724NIA NIH HHS R01 AG061788NIA NIH HHS R01 AG062276NIA NIH HHS R01 AG067781NIA NIH HHS R01 AG068338NIA NIH HHS R01 AG069453NIA NIH HHS R01 AG073235NIA NIH HHS R01 AG077444NIA NIH HHS R01 AG079280NIA NIH HHS R35 AG072262NIA NIH HHS R56 AG045571NIA NIH HHS R56 AG074321NIA NIH HHS U01 AG024904NIA NIH HHS U01 AG057195NIA NIH HHS U19 AG063911NIA NIH HHS U19 AG073153NIA NIH HHS U24 AG067418NIA NIH HHS U24 AG072122NIBIB NIH HHS R01 EB009352NIDCD NIH HHS R01 DC008552NIH HHS S10 OD026738NIMH NIH HHS P50 MH071616NINDS NIH HHS P30 NS098577NINDS NIH HHS R01 NS075075NINDS NIH HHS U19 NS120384RRD VA I01 RX001534RRD VA I21 RX001381
6 · The paper itself

Abstract

Structural MRI is routinely acquired in the clinical assessment of Alzheimer's disease, yet quantitative morphometric indices derived from these scans remain largely confined to research settings. Here we present PHASE-AD - a framework that translates such indices into clinically interpretable classifications of atrophy subtype and stage that jointly capture atrophy progression while accounting for inter-individual atrophy heterogeneity. PHASE-AD is trained on MRI scans from 8,415 participants and robustly captures limbic-predominant and hippocampal-sparing atrophy subtypes that were identified across seven independent datasets. Two cross-validation schemes revealed high robustness across different field strength and scanner manufacturer configurations. Atrophy classifications were associated with diverging clinical profiles and tau accumulation patterns. In prospective designs mirroring contemporary AD trials, they stratified longitudinal cognitive trajectories and outperformed semi-quantitative visual MRI assessments as a clinically established comparator. These findings support the integration of automated atrophy subtyping and staging into clinical practice and pharmacological trials.

Identifiers

PMID42428079
PMCPMC13345447

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.